Speaker

 

 

Fleur Ferguson received her Ph.D in Chemistry from the University of Cambridge, advised by Prof. Chris Abell and Prof. Alessio Ciulli. She then joined Dana-Farber Cancer Institute at Harvard Medical School, where she performed her postdoctoral research in the laboratory of Prof. Nathanael Gray. Here, her research focused on modulating kinases with reversible inhibitors, covalent inhibitors, and targeted protein degradation, as well as applying TPD to undruggable targets in neurodegeneration. Dr. Ferguson is currently an Assistant Professor in the Department of Chemistry and Biochemistry, and the Skaggs School of Pharmacy and Pharmaceutical Sciences, at the University of California, San Diego. Her academic research group focuses on the development and application of proximity-pharmacology technologies to disease areas where traditional targeted therapies have failed, such as neurodegeneration.

« Go Back